Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The benefits? Risk is assessed more rapidly and at a cheaper cost.
Rubraca shrank tumors and lowered PSA levels in men with advanced prostate cancer.
Whole-genome analysis of aggressive disease offers insights into possible personalized therapies
An estimated 29,430 men will die from prostate cancer in 2018; it is second only to lung cancer as a cause of cancer death among U.S. men.
Studies show African-American men may respond better to treatment and survive longer.
Erleada delayed cancer progression and death by two years in a Phase III trial.
Erleada prolonged the time to disease progression or death in the SPARTAN trial.
Xtandi and Erleada both prolonged the time to disease progression or death by about two years.
Approval was based on LATITUDE trial of patients with metastatic high-risk castration-sensitive prostate cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.